Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model

Oncotarget

Volumn 8, Issue 21, 2017, Pages 34141-34163

  Minas, Tsion Zewdu ^a   Surdez, Didier ^b   Javaheri, Tahereh ^c   Tanaka, Miwa ^d   Howarth, Michelle ^e   Kang, Hong Jun ^f   Han, Jenny ^a   Han, Zhi Yan ^b   Sax, Barbara ^c   Kream, Barbara E ^g   Hong, Sung Hyeok ^a   çelik, Haydar ^a   Tirode, Franck ^b   Tuckermann, Jan ^h   Toretsky, Jeffrey A ^a   Kenner, Lukas ^c,i,j   Kovar, Heinrich ^i,k   Lee, Sean ^f   Sweet Cordero, E Alejandro ^e   Nakamura, Takuro ^d   Moriggl, Richard ^c,i,j   Delattre, Olivier ^b,l   Üren, Aykut ^a   more..

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUT CURIE   (France)

^c Ludwig Boltzmann Institute for Cancer Research (LBI CR)   (Australia)

^d CANCER INSTITUTE   (Japan)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h UNIVERSITY OF ULM   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^k ST ANNA CHILDREN S HOSPITAL   (Austria)

^l INSTITUT CURIE   (France)

more..

Author keywords

Ewing sarcoma; EWS FLI1; EWS FLI1 driven transgenic mouse model

Indexed keywords

CRE RECOMBINASE; ONCOPROTEIN; PROTEIN FLI1; RNA BINDING PROTEIN EWS; UNCLASSIFIED DRUG; EWS-FLI FUSION PROTEIN; TRANSCRIPTION FACTOR FLI 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLASTOCYST; CAG GENE; CELL LINEAGE; COL1A2.3 GENE; COL1A3.6 GENE; COMET ASSAY; CONTROLLED STUDY; DERMO1 GENE; EWING SARCOMA; EWS FLI1 GENE; FLOW CYTOMETRY; GENE CASSETTE; GENE TRANSFER; GENETIC RECOMBINATION; HOMOZYGOSITY; IMMUNOPHENOTYPING; LUCIFERASE ASSAY; MOUSE; NEFL GENE; NONHUMAN; NSE GENE; ONCOGENE; OSTEOBLAST; OSTERIX GENE; P0 GENE; POLYADENYLATION; PROMOTER REGION; PROTEIN EXPRESSION; PRX1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; RUNX2 GENE; SOX9 GENE; TRANSGENE; TRANSPOSON; UBIQUITINATION; ADENOVIRIDAE; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE KNOCK-IN; GENETICS; HUMAN; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING;

EID: 85019849702     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9388     Document Type: Article

References (106)

1. Arndt CA and Crist WM. Common musculoskeletal tumors of childhood and adolescence. The New England journal of medicine. 1999; 341:342-352
2. Potratz J, Dirksen U, Jurgens H and Craft A. Ewing sarcoma: clinical state-of-the-art. Pediatric hematology and oncology. 2012; 29:1-11
3. Tsokos M, Alaggio RD, Dehner LP and Dickman PS. Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors. Pediatric and developmental pathology. 2012; 15:108-126
4. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G and et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992; 359:162-165
5. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R and Denny CT. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Molecular and Cellular Biology. 1993; 13:7393-7398
6. Tanaka K, Iwakuma T, Harimaya K, Sato H and Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. The Journal of clinical investigation. 1997; 99:239-247
7. Toretsky JA, Connell Y, Neckers L and Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol. 1997; 31:9-16
8. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Thomas G and Gadner H. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 1996; 7:429-437
9. Maksimenko A, Lambert G, Bertrand JR, Fattal E, Couvreur P and Malvy C. Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Ann N Y Acad Sci. 2003; 1002:72-77
10. Ouchida M, Ohno T, Fujimura Y, Rao VN and Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene. 1995; 11:1049-1054
11. Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska-Kwiatkowska A, Blackburn M, Chansky K, Conrad EU, 3rd, Bruckner JD, Greenlee TK and Yang L. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res. 2004; 22:910-917
12. Dohjima T, Lee NS, Li H, Ohno T and Rossi JJ. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther. 2003; 7:811-816
13. Kovar H, Ban J and Pospisilova S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol. 2003; 13:275-281
14. Deneen B and Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene. 2001; 20:6731-6741
15. Lessnick SL, Dacwag CS and Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer cell. 2002; 1:393-401
16. Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL and Lee SB. EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer research. 2010; 70:1154-1163
17. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A and Stamenkovic I. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer research. 2005; 65:11459-11468
18. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V and Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer research. 2008; 68:2176-2185
19. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA and Ilaria RL, Jr. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer research. 2005; 65:8698-8705
20. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, Hsu JH and Lawlor ER. Modeling initiation of Ewing sarcoma in human neural crest cells. Plos One. 2011; 6:e19305
21. Tanaka M, Yamazaki Y, Kanno Y, Igarashi K, Aisaki K, Kanno J and Nakamura T. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. The Journal of clinical investigation. 2014; 124:3061-3074
22. De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL and Nanni P. Molecular and cellular biology of rhabdomyosarcoma. Future Oncol. 2009; 5:1449-1475
23. Haldar M, Randall RL and Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clinical orthopaedics and related research. 2008; 466:2156-2167
24. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA and Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004; 18:2614-2626
25. Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C, Taub RN and Matushansky I. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. The Journal of clinical investigation. 2012; 122:886-898
26. Yamada K, Ohno T, Aoki H, Semi K, Watanabe A, Moritake H, Shiozawa S, Kunisada T, Kobayashi Y, Toguchida J, Shimizu K, Hara A and Yamada Y. EWS/ATF1 expression induces sarcomas from neural crestderived cells in mice. The Journal of clinical investigation. 2013; 123:600-610
27. Haldar M, Hancock JD, Coffin CM, Lessnick SL and Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer cell. 2007; 11:375-388
28. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM and Lozano G. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer research. 2008; 68:8968-8975
29. Torchia EC, Boyd K, Rehg JE, Qu C and Baker SJ. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Molecular and cellular biology. 2007; 27:7918-7934
30. Tanaka M, Yamaguchi S, Yamazaki Y, Kinoshita H, Kuwahara K, Nakao K, Jay PY, Noda T and Nakamura T. Somatic chromosomal translocation between Ewsr1 and Fli1 loci leads to dilated cardiomyopathy in a mouse model. Sci Rep. 2015; 5:7826
31. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A and Toretsky JA. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nature medicine. 2009; 15:750-756
32. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA and Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. The Journal of clinical investigation. 2011; 121:148-160
33. Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D and Amatruda JF. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWSFLI1 tumorigenesis. Disease models & mechanisms. 2012; 5:95-106
34. Jeong JH, Jin JS, Kim HN, Kang SM, Liu JC, Lengner CJ, Otto F, Mundlos S, Stein JL, van Wijnen AJ, Lian JB, Stein GS and Choi JY. Expression of Runx2 transcription factor in non-skeletal tissues, sperm and brain. J Cell Physiol. 2008; 217:511-517
35. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010; 11:517-531
36. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, Wu G, Chen X, Pierron G, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer discovery. 2014; 4:1342-1353
37. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D and DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996; 85:27-37
38. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR and de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002; 108:17-29
39. Rodda SJ and McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133:3231-3244
40. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, Alt FW, McMahon AP and Orkin SH. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22:1662-1676
41. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM and Long F. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. Plos One. 2014; 9:e85161
42. Zomer A, Maynard C, Verweij FJ, Kamermans A, Schafer R, Beerling E, Schiffelers RM, de Wit E, Berenguer J, Ellenbroek SIJ, Wurdinger T, Pegtel DM and van Rheenen J. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior. Cell. 2015; 161:1046-1057
43. Liu F, Woitge HW, Braut A, Kronenberg MS, Lichtler AC, Mina M and Kream BE. Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol. 2004; 48:645-653
44. Horowitz M, DeLaney, T, Malawer, M, Tsokos, M (1993). Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. (Philadelphia: Lippincott)
45. Beaudet L, Charron G, Houle D, Tretjakoff I, Peterson A and Julien JP. Intragenic regulatory elements contribute to transcriptional control of the neurofilament light gene. Gene. 1992; 116:205-214
46. Albert H, Dale EC, Lee E and Ow DW. Site-specific integration of DNA into wild-type and mutant lox sites placed in the plant genome. Plant J. 1995; 7:649-659
47. Strathdee D, Ibbotson H and Grant SG. Expression of transgenes targeted to the Gt(ROSA)26Sor locus is orientation dependent. PLoS One. 2006; 1:e4
48. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999; 21:70-71
49. Scacheri PC, Crabtree JS, Novotny EA, Garrett-Beal L, Chen A, Edgemon KA, Marx SJ, Spiegel AM, Chandrasekharappa SC and Collins FS. Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis. 2001; 30:259-263
50. Logan M, Martin JF, Nagy A, Lobe C, Olson EN and Tabin CJ. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis. 2002; 33:77-80
51. Schwenk F, Baron U and Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995; 23:5080-5081
52. Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA and Ornitz DM. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development. 2003; 130:3063-3074
53. Florin L, Alter H, Grone HJ, Szabowski A, Schutz G and Angel P. Cre recombinase-mediated gene targeting of mesenchymal cells. Genesis. 2004; 38:139-144
54. Akiyama H, Kim JE, Nakashima K, Balmes G, Iwai N, Deng JM, Zhang Z, Martin JF, Behringer RR, Nakamura T and de Crombrugghe B. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. P Natl Acad Sci USA. 2005; 102:14665-14670
55. Yamauchi Y, Abe K, Mantani A, Hitoshi Y, Suzuki M, Osuzu F, Kuratani S and Yamamura K. A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. Dev Biol. 1999; 212:191-203
56. Shiota M, Heike T, Haruyama M, Baba S, Tsuchiya A, Fujino H, Kobayashi H, Kato T, Umeda K, Yoshimoto M and Nakahata T. Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties. Exp Cell Res. 2007; 313:1008-1023
57. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF and Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood. 2004; 103:1662-1668
58. Cadinanos J and Bradley A. Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Res. 2007; 35:e87
59. Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K and Suzuki N. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006; 25:7673-7679
60. Meuwissen R, Linn SC, van der Valk M, Mooi WJ and Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene. 2001; 20:6551-6558
61. Ueda S, Fukamachi K, Matsuoka Y, Takasuka N, Takeshita F, Naito A, Iigo M, Alexander DB, Moore MA, Saito I, Ochiya T and Tsuda H. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis. 2006; 27:2497-2510
62. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, Bronson RT, Mahmood U and Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. P Natl Acad Sci USA. 2010; 107:1565-1570
63. Zwerner JP, Guimbellot J and May WA. EWS/FLI function varies in different cellular backgrounds. Experimental cell research. 2003; 290:414-419
64. Navarro D, Agra N, Pestana A, Alonso J and Gonzalez-Sancho JM. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis. 2010; 31:394-401
65. Fevr T, Robine S, Louvard D and Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol. 2007; 27:7551-7559
66. Crozat A, Aman P, Mandahl N and Ron D. Fusion of Chop to a Novel Rna-Binding Protein in Human Myxoid Liposarcoma. Nature. 1993; 363:640-644
67. Sonobe H, Takeuchi T, Taguchi T, Shimizu K, Iwata J, Furihata M and Ohtsuki Y. Further characterization of the human clear cell sarcoma cell line HS-MM demonstrating a specific t(12;22)(q13;q12) translocation and hybrid EWS/ATF-1 transcript. J Pathol. 1999; 187:594-597
68. Burns JS, Abdallah BM, Schroder HD and Kassem M. The histopathology of a human mesenchymal stem cell experimental tumor model: support for an hMSC origin for Ewing's sarcoma? Histology and histopathology. 2008; 23:1229-1240
69. Lin PP, Wang Y and Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma. 2011; 2011
70. Potikyan G, France KA, Carlson MR, Dong J, Nelson SF and Denny CT. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors. Laboratory investigation. 2008; 88:1291-1302
71. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P and Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer cell. 2007; 11:421-429
72. Li X, McGee-Lawrence ME, Decker M and Westendorf JJ. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem. 2010; 111:933-943
73. Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suva ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, Formey A, Patel A, Gymrek M, Thapar V, Deshpande V, Ting DT, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer cell. 2014; 26:668-681
74. Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schonegger A, Datlinger P, Kubicek S, Bock C and Kovar H. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 2015; 10:1082-1095
75. Kovar H. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opin Ther Targets. 2014; 18:1315-1328
76. Chen J and Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene. 2015; 34:1-14
77. Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Uren A and Toretsky JA. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. P Natl Acad Sci USA. 2015; 112:E1307-1316
78. Knoop LL and Baker SJ. EWS/FLI alters 5 '-splice site selection. Journal of Biological Chemistry. 2001; 276:22317-22322
79. Yang L, Chansky HA and Hickstein DD. EWS center dot Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. Journal of Biological Chemistry. 2000; 275:37612-37618
80. Chansky HA, Hu M, Hickstein DD and Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 2001; 61:3586-3590
81. Kovar H, Jug G, Hattinger C, Spahn L, Aryee DN, Ambros PF, Zoubek A and Gadner H. The EWS protein is dispensable for Ewing tumor growth. Cancer Res. 2001; 61:5992-5997
82. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ and Lessnick SL. Microsatellites as EWIS/FLI response elements in Ewing's sarcoma. P Natl Acad Sci USA. 2008; 105:10149-10154
83. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D and Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene. 2009; 28:4126-4132
84. Gangwal K, Close D, Enriquez CA, Hill CP and Lessnick SL. Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma. Genes Cancer. 2010; 1:177-187
85. Monument MJ, Johnson KM, Grossmann AH, Schiffman JD, Randall RL and Lessnick SL. Microsatellites with Macro-Influence in Ewing Sarcoma. Genes-Basel. 2012; 3:444-460
86. Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, Jorde LB, Randall RL and Lessnick SL. EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genet-Ny. 2012; 205:304-312
87. Monument MJ, Johnson KM, McIlvaine E, Abegglen L, Watkins WS, Jorde LB, Womer RB, Beeler N, Monovich L, Lawlor ER, Bridge JA, Schiffman JD, Krailo MD, Randall RL and Lessnick SL. Clinical and Biochemical Function of Polymorphic NR0B1 GGAA-Microsatellites in Ewing Sarcoma: A Report from the Children's Oncology Group. Plos One. 2014; 9
88. Grunewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, Mirabeau O, Cidre-Aranaz F, Tirode F, Zaidi S, Perot G, Jonker AH, Lucchesi C, Le Deley MC, Oberlin O, Marec-Berard P, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet. 2015; 47:1073-1078
89. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H and Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1991; 67:1886-1893
90. Kovar H, Dworzak M, Strehl S, Schnell E, Ambros IM, Ambros PF and Gadner H. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene. 1990; 5:1067-1070
91. Fellinger EJ, Garin-Chesa P, Triche TJ, Huvos AG and Rettig WJ. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. The American journal of pathology. 1991; 139:317-325
92. Perlman EJ, Dickman PS, Askin FB, Grier HE, Miser JS and Link MP. Ewing's sarcoma-routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Human pathology. 1994; 25:304-307
93. Kreppel M, Aryee DN, Schaefer KL, Amann G, Kofler R, Poremba C and Kovar H. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells. Oncogene. 2006; 25:2795-2800
94. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M, Lollini PL, Nanni P, Nicoletti G, Bernard G, Bernard A and Picci P. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer research. 2000; 60:5134-5142
95. Sohn HW, Choi EY, Kim SH, Lee IS, Chung DH, Sung UA, Hwang DH, Cho SS, Jun BH, Jang JJ, Chi JG and Park SH. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. The American journal of pathology. 1998; 153:1937-1945
96. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P and Scotlandi K. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. The Journal of clinical investigation. 2010; 120:668-680
97. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, Curti A, Manara MC, Benini S, Bernard A and Picci P. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. European journal of cancer. 2006; 42:91-96
98. Bixel G, Kloep S, Butz S, Petri B, Engelhardt B and Vestweber D. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood. 2004; 104:3205-3213
99. Suh YH, Shin YK, Kook MC, Oh KI, Park WS, Kim SH, Lee IS, Park HJ, Huh TL and Park SH. Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs. Gene. 2003; 307:63-76
100. Elzi DJ, Song M, Houghton PJ, Chen Y and Shiio Y. The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Genes & cancer. 2015; 6:452-461
101. Stock M and Otto F. Control of RUNX2 isoform expression: the role of promoters and enhancers. J Cell Biochem. 2005; 95:506-517
102. Melot T, Gruel N, Doubeikovski A, Sevenet N, Teillaud JL and Delattre O. Production and characterization of mouse monoclonal antibodies to wild-type and oncogenic FLI-1 proteins. Hybridoma. 1997; 16:457-464
103. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS and DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & development. 2003; 17:3112-3126
104. Chan CK, Chen CC, Luppen CA, Kim JB, DeBoer AT, Wei K, Helms JA, Kuo CJ, Kraft DL and Weissman IL. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature. 2009; 457:490-494
105. Viatour P, Somervaille TC, Venkatasubrahmanyam S, Kogan S, McLaughlin ME, Weissman IL, Butte AJ, Passegue E and Sage J. Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell. 2008; 3:416-428
106. Forss-Petter S, Danielson PE, Catsicas S, Battenberg E, Price J, Nerenberg M and Sutcliffe JG. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron. 1990; 5:187-197